Top-line Final Data from Cantrixil Phase I Study Confirms Prio...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
SYDNEY, Dec. 9, 2020 /PRNewswire-AsiaNet/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share top-line final data from its phase I study of Cantrixil (TRX-E-002-1) in patients with persistent or recurrent ovarian c...
Authors: LATEST ASIANET NEWS RELEASES